The World Health Organization (WHO) has recommended a trial of the Ervebo vaccine in the Democratic Republic of the Congo (DRC) as the country reports over 4,000 confirmed Ebola cases. The recommendation follows preliminary findings from animal studies suggesting that Ervebo could offer some cross-protection against the Bundibugyo virus, which is responsible for the current outbreak (eastleighvoice.co.ke).
The Bundibugyo epidemic, described as the world’s second-largest and fastest-spreading on record, has raised urgent concerns among health officials. With cases continuing to rise, the WHO is urging rapid action to test the vaccine’s potential in human trials. This comes as the DRC struggles to contain the outbreak, which has affected multiple regions and led to significant loss of life (aljazeera.com).
Health authorities in the DRC are working closely with international partners to implement the vaccine trial. The Ervebo vaccine, previously used in the 2014-2016 Ebola outbreak in West Africa, has shown effectiveness against the Zaire ebolavirus. However, its efficacy against the Bundibugyo strain remains under evaluation. The trial could provide critical insights into its broader application in the ongoing crisis.
